Enterprise Value

8.994M

Cash

3.84M

Avg Qtr Burn

-6.133M

Short % of Float

1.32%

Insider Ownership

28.29%

Institutional Own.

42.71%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Ameluz (aminolevulinic acid hydrochloride) Details
BCC (basal cell carcinoma), AK (actinic keratosis)

Approved

Quarterly sales

PDUFA

Approval decision

Ameluz® Details
Actinic keratosis

Phase 3

Data readout

Phase 2

Data readout